Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities

3 Months Ended

Mar. 31, 2017

12. Accrued Expenses and Other Long-Term Liabilities

Accrued expenses and other long-term liabilities, excluding National, consisted of the following:

	March 31,		December 31,
($ in thousands)	2017		2016
Accrued expenses:
Professional fees	$	1,450	$	1,253
Salaries, bonuses and related benefits		3,532		2,846
Accrued Severance		-		53
Ovamed manufacturing rights short term component		900		900
Research and development		680		394
Dr. Falk Pharma milestone		2,684		2,634
Other		1,874		2,002
Total accrued expenses	$	11,120	$	10,082

Other long-term liabilities:
Deferred rent and long-term lease abandonment charge		5,020		5,014
Total other long-term liabilities	$	5,020	$	5,014

National’s accounts payable and other accrued expenses as of December 31, 2016, consisted of the following:

	December 31,
	2016
Legal	$	752
Audit		263
Telecommunications		178
Data Services		235
Regulatory		623
Settlements		421
Deferred rent		123
Contingent consideration payable		623
Other		1,995
Total	$	5,213